A 1536-Well Fluorescence Polarization Assay to Screen for Modulators of the MUSASHI Family of RNA-Binding Proteins
- 16 July 2014
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Combinatorial Chemistry & High Throughput Screening
- Vol. 17 (7) , 596-609
Abstract
RNA-binding proteins (RBPs) can act as stem cell modulators and oncogenic drivers, but have been largely ignored by the pharmaceutical industry as potential therapeutic targets for cancer. The MUSASHI (MSI) family has recently been demonstrated to be an attractive clinical target in the most aggressive cancers. Therefore, the discovery and development of small molecule inhibitors could provide a novel therapeutic strategy. In order to find novel compounds with MSI RNA binding inhibitory activity, we have developed a fluorescence polarization (FP) assay and optimized it for high throughput screening (HTS) in a 1536-well microtiter plate format. Using a chemical library of 6,208 compounds, we performed pilot screens, against both MSI1 and MSI2, leading to the identification of 7 molecules for MSI1, 15 for MSI2 and 5 that inhibited both. A secondary FP dose-response screen validated 3 MSI inhibitors with IC50 below 10 μM. Out of the 25 compounds retested in the secondary screen only 8 demonstrated optical interference due to high fluorescence. Utilizing a SYBR-based RNA electrophoresis mobility shift assay (EMSA), we further verified MSI inhibition of the top 3 compounds. Surprisingly, even though several aminoglycosides were present in the library, they failed to demonstrate MSI inhibitor activity challenging the concept that these compounds are pan-active against RBPs. In summary, we have developed an in vitro strategy to identify MSI specific inhibitors using an FP HTS platform, which will facilitate novel drug discovery for this class of RBPs.Keywords
This publication has 33 references indexed in Scilit:
- Identification of Influenza Virus Inhibitors Targeting NS1A Utilizing Fluorescence Polarization–Based High-Throughput AssaySLAS Discovery, 2012
- Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancerThe Journal of Pathology, 2012
- Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungsNature Medicine, 2011
- Msi-1 is a Predictor of Survival and a Novel Therapeutic Target in Colon CancerAnnals of Surgical Oncology, 2011
- Regulation of myeloid leukaemia by the cell-fate determinant MusashiNature, 2010
- Deletion of the RNA-binding proteins ZFP36L1 and ZFP36L2 leads to perturbed thymic development and T lymphoblastic leukemiaNature Immunology, 2010
- Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemiaNature Medicine, 2010
- Lin28 promotes transformation and is associated with advanced human malignanciesNature Genetics, 2009
- Nucleobase-Specific Enhancement of Cy3 FluorescenceJournal of Fluorescence, 2008
- Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysisNature Biotechnology, 2008